



## **COMUNICACIÓN DE HECHO RELEVANTE**

**ATRYS HEALTH, S.A.**

25 de septiembre de 2019

En virtud de lo previsto en el artículo 17 del Reglamento (UE) nº 596/2014 sobre abuso de mercado y en el artículo 228 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre, y disposiciones concordantes, así como en la Circular 6/2018 del Mercado Alternativo Bursátil (MAB), ponemos en su conocimiento:

### **Presentación en ASEBIO INVERSTORS DAY 2019.**

Quedamos a su disposición para cuantas aclaraciones consideren oportunas.

Madrid, 25 de septiembre de 2019

Doña Isabel Lozano Fernández  
Consejera Delegada de ATRYS HEALTH S.A.



A Step Forward in Healthcare

## Corporate Presentation



asebio INVESTORS DAY – 2019

## OUR RATIONALE



**Long term favourable sector trend**



### **Aging population:**

- + Oncology.
- + Medical specialists shortage.
- + Increasing healthcare expenditure.



**Positioned in healthcare segments with high profit margins**



Gross Margin: **60-70%**

EBITDA Margin: **25-35%**



**Clear value proposition**



+ Precision medicine services

+ Bringing innovation to improve the efficiency of health systems.



**Atomized sector structure**



To build up an attractive large project in healthcare services

# OUR BUSINESS LINES



## Oncology Diagnostic Services

Comprehensive characterization of biological samples

**Gross Margin**

60-70%

**EBITDA Margin**

20-25%

**Initial Capex**

Medium

**Operating Capex**

Low

## Online Diagnostics Services

Bringing diagnostic services 24 x 7 x 365

**Gross Margin**

40-50%

**EBITDA Margin**

15-20%

**Initial Capex**

Low

**Operating Capex**

Low

## High precision radiotherapy services

**Gross Margin**

90-95%

**EBITDA Margin**

35-45%

**Initial Capex**

High

**Operating Capex**

Low

## Smart Data

**Gross Margin**

95%

**EBITDA Margin**

60%

**Initial Capex**

Low

**Operating Capex**

Low

## INORGANIC GROWTH STRATEGY

Four strategic acquisitions already executed in last 15 month

- Average EV/EBITDA multiple:

**6,8x**

- Average structure transactions:

**68% cash**

**32% Atrys shares**



INTERNATIONAL  
TELEMEDICINE  
HOSPITAL

Online Diagnostics Services

jul.  
2018



LLEBALUST  
Patología

Oncology Diagnostic Services

nov.  
2018



Real Life Data

Smart Data

jun.  
2019



TELERRADIOLOGÍA  
de COLOMBIA  
DIAGNÓSTICO DIGITAL ESPECIALIZADO S.A.S

Online Diagnostics Services

oct.  
2019

## FUNDS SOURCES

**2018**

**12MEUR**

Capital increase

**2019**

**25MEUR**

MARF Bond Program

5 years maturity

Rating: BB-

3mEuribor + 5,5%


**5MEUR**

Capital Increase (oct)

Linked to a 5<sup>th</sup> company acquisition

## Main Figures Evolution ( 2014-2018 )

The company has positioned itself as a benchmark player, executing a strategy that combines organic growth of 10% in 2018 (like for like) with acquisitions of high added value to strengthen the vectors of growth.



(\*) Proforma includes full year impact of International Telemedicine Hospital (jul 2018) + Llebalust Patología S.L. (nov. 2018) acquisitions.


## Market Cap:

**76** MEUR


## Stock Price Evolution



## A Balanced shareholders distribution



## Steady increase in our traded shares volume



## Legal Notice

This document has been drawn up by ATRYS HEALTH, S.A. (hereinafter “ATRYS” or the “Company”) exclusively for informative purposes. Therefore, it may not be disclosed or used for any purpose other than the aforesaid without the express written consent of the Company.

This document is based on information in the public domain and/or on data provided by the Company. In accordance with the provisions of the Securities Market Law (consolidated text approved by Royal Legislative Decree 4/2015 dated 23 October), Royal Decree 5/2005 dated 11 March and/or Royal Decree 1310/2005 dated 4 November with their respective amendments and implementing regulations, this document does not constitute a public offer or an invitation to purchase, sell or subscribe shares or any other type of security. This notification does not constitute an offer of securities or a request for an offer to sell or buy securities. Securities shall not be sold in any jurisdiction in which such offers, requests or sales are illegal prior to registration or qualification under the securities laws of said jurisdictions.

This document may contain projections, forecasts or future estimates based on expectations, forecasts and current hypotheses about future events that, given their nature, do not imply a guarantee of future performance and involve implicit known and unknown assumptions, risks and uncertainties regarding the Atrys Group and its investments, including, among others, the development of its business, its growth plan, trends in its operations sector and its capital outlays and future acquisitions. In view of these risks, uncertainties and hypotheses, projections, forecasts or future estimates may not be met. The actual outcomes, performance or achievements may differ significantly from the outcomes, performance or future achievements set forth or implied in this document.

These risks and uncertainties include those identified in the documents that the Company has forwarded to the Alternative Investment Market.

Unless legally required to do so, the Company does not undertake to place these forecasts, projections, estimates or future circumstances on public record, update or revise them even if actual future events or circumstances, including but not limited to changes to the Company's business or to its acquisition strategy, clearly reveal that the projected performance of the businesses, conditions or events set forth or implicitly mentioned in this document will not be carried out. This document may contain summarised information or data that has not been reviewed, audited or verified by independent third parties including the auditors of the Company's accounts. Said information is subject to negotiations, changes and amendments and must therefore be read as a whole, taking the rest of the information available to the public into account including, as required, any other document published by the Company in the future.

Pursuant to the above, neither the Company, its group companies nor their respective directors, executives, staff, consultants or advisers (herein referred to as their representatives), decline to provide or grant any express or implied guarantee as to the accuracy, relevance or comprehensiveness of the information or statements included in this document or, in particular, on the future fulfilment of the forecasts, projections, estimates or future circumstances dealt with in this document. Both the Company and its representatives decline all responsibility whatsoever for any loss or damage that may arise from the use of this document or the information contained herein.



Atrys 

**Thank You**





# Atrys

*Contacto:*  
*José Maria Huch*  
*CFO*  
[\*jmhuch@atryshealth.com\*](mailto:jmhuch@atryshealth.com)  
*T. (34) 699.433.599*